Prevention and monitoring of superficial bladder TCC recurrences
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Bladder cancer is still a topical problem because of constant growth of its incidence and mortality rates.
The objective. An aim of our investigation was a study of the efficacy and results of adjuvant intravesical chemotherapy in patients suffering on non-muscle invasive bladder TCC.
Materials and methods. 86 Bladder TCC patients were included in a retrospective study; duration of observation had been varied from five to 60 months. All patients have underwent TURBT with subsequent adjuvant intravesical chemotherapy: Doxorubicin 50mg was the most common drug choice (44 patients, 51.2%) with 1 hr exposition time and following five the same instillations once a week. Mitomycin 40 mg was introduced in 32 patients (37.2%) with 1 hr exposition time and subsequent five instillations once a week. BCG was used in 10 patients (11.6%) once a week for a six times.
Results. Cases of recurrence were observed in all groups of patients and accounted for 11.6%. Percentage of relapse was higher in the group of patients who underwent instillations with doxorubicin and was 6 cases (13.6%), in contrast to the group of mitomycin, where 3 relapses were observed (9.3%) (p <0.05), and in the BCG group 1 patient. «Gold» standard in the treatment of superficial bladder cancer in our opinion is TURBT that allows to remove the tumor radically. Intravesical chemotherapy immediately after TUR tumors significantly reduces the risk of progression of cancer.
Conclusion. It has been proved a significant improvement in relapsefree period and an increase in patient survival in patients treated with adjuvant intravesical mitomycin C therapy in comparison with patients treated with doxorubicin.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Bjuleten' nacional'nogo kancerrejestru Ukrai'ni № 15 – «Rak v Ukrai'ni». – Nacional'nij institut raku. – K., 2014.
Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation for Non-muscle Invasive Bladder Cancer / H.L. Ke, J. Lin, Y. Ye [et al.] // Ann. Surg. Oncol. – 2015. – Nov. – Vol. 22 (12). – P. 4104–4110.
Follow-up of urothelial carcinoma: Review of the Cancer Committee of the French Association of Urology / P. Colin, Y. Neuzillet, G. Pignot [et al.]; membres du Comitj de cancjrologie de l’Association franzaise d’urologie // Prog. Urol. – 2015. – Sep. – Vol. 25 (10). – P. 616–624.
Messing E.M. Campbell’s Urology / E.M. Messing, W. Catalona; eds. P.C. Walsh [et al.]. – Philadelphia: WB Saunders, 1998. – P. 2327–2426.
Guillaume L. Epidemiology of and risk factors for bladder cancer and for urothelial tumors / L. Guillaume, L. Guy // Rev. Prat. – 2014. – Dec. – Vol. 64 (10). – P. 1372–1374, 1378–1380.
Klinichni rekomendacii' z onkourologichnih zahvorjuvan' / Za zag. red. E.O. Stahovs'kogo. – Donec'k, 2011. – 296 s.
Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity / Y. Patil, Y. Amitay, P. Ohana [et al.] // J. Control Release. – 2016. – Jan 22. pii: S01683659(16)30035–9.
Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus CalmetteGujrin for Adjuvant Treatment of Patients with Intermediateand High-risk NonMuscle-invasive Bladder Cancer / T.J. Arends, O. Nativ, M. Maffezzini [et al.] // Eur. Urol. – 2016. – Jan 20. pii: S03022838(16)00057–9.
